Elvin D. de Araujo
Elvin D. de Araujo
Verified email at utoronto.ca
Title
Cited by
Cited by
Year
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ...
Leukemia 32 (5), 1135-1146, 2018
672018
CD133+ brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence
N Garg, D Bakhshinyan, C Venugopal, S Mahendram, DA Rosa, ...
Oncogene 36 (5), 606-617, 2017
282017
Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)‐Resistant CML Lines While Circumventing Pharmacokinetic Liabilities
AM Ali, RF Gómez‐Biagi, DA Rosa, PS Lai, WL Heaton, JS Park, ...
ChemMedChem 11 (8), 850-861, 2016
242016
Direct targeting options for STAT3 and STAT5 in cancer
A Orlova, C Wagner, ED de Araujo, D Bajusz, HA Neubauer, M Herling, ...
Cancers 11 (12), 1930, 2019
212019
Structural and functional consequences of the STAT5B N642H driver mutation
ED de Araujo, F Erdogan, HA Neubauer, D Meneksedag-Erol, ...
Nature communications 10 (1), 1-15, 2019
192019
The first nucleotide binding domain of the sulfonylurea receptor 2A contains regulatory elements and is folded and functions as an independent module
ED de Araujo, LK Ikeda, S Tzvetkova, V Kanelis
Biochemistry 50 (31), 6655-6666, 2011
182011
The ERBB-STAT3 axis drives Tasmanian devil facial tumor disease
L Kosack, B Wingelhofer, A Popa, A Orlova, B Agerer, B Vilagos, P Majek, ...
Cancer Cell 35 (1), 125-139. e9, 2019
162019
High-throughput thermofluor-based assays for inhibitor screening of STAT SH2 domains
ED de Araujo, P Manaswiyoungkul, J Israelian, J Park, K Yuen, ...
Journal of Pharmaceutical and Biomedical Analysis 143, 159-167, 2017
162017
Physiological characterization and light response of the CO2-concentrating mechanism in the filamentous cyanobacterium Leptolyngbya sp. CPCC 696
ED de Araujo, J Patel, C de Araujo, SP Rogers, SM Short, DA Campbell, ...
Photosynthesis research 109 (1-3), 85-101, 2011
162011
Phosphorylation-dependent changes in nucleotide binding, conformation, and dynamics of the first nucleotide binding domain (NBD1) of the sulfonylurea receptor 2B (SUR2B)
ED De Araujo, CP Alvarez, JP López-Alonso, CR Sooklal, M Stagljar, ...
Journal of Biological Chemistry 290 (37), 22699-22714, 2015
142015
Regulating the Master Regulator: Controlling Ubiquitination by Thinking Outside the Active Site: Miniperspective
SL Paiva, SR da Silva, ED De Araujo, PT Gunning
Journal of medicinal chemistry 61 (2), 405-421, 2018
112018
Successful development and use of a thermodynamic stability screen for optimizing the yield of nucleotide binding domains
ED de Araujo, V Kanelis
Protein expression and purification 103, 38-47, 2014
112014
NMR and fluorescence studies of drug binding to the first nucleotide binding domain of SUR2A
JP López-Alonso, ED de Araujo, V Kanelis
Biochemistry 51 (45), 9211-9222, 2012
112012
A functional in vitro assay for screening inhibitors of STAT5B phosphorylation
ED de Araujo, P Manaswiyoungkul, F Erdogan, AK Qadree, D Sina, G Tin, ...
Journal of pharmaceutical and biomedical analysis 162, 60-65, 2019
102019
Strategies for over-expression and purification of recombinant full length STAT5B in Escherichia coli
ED de Araujo, M Geletu, PT Gunning
Protein expression and purification 129, 1-8, 2017
82017
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer
AE Shouksmith, F Shah, ML Grimard, JM Gawel, YS Raouf, M Geletu, ...
Journal of medicinal chemistry 62 (5), 2651-2665, 2019
72019
Characterization and application studies of ProxyPhos, a chemosensor for the detection of proximally phosphorylated peptides and proteins in aqueous solutions
D Kraskouskaya, AD Cabral, R Fong, M Bancerz, K Toutah, D Rosa, ...
Analyst 142 (13), 2451-2459, 2017
72017
Structural Implications of STAT3 and STAT5 SH2 Domain Mutations
ED de Araujo, A Orlova, HA Neubauer, D Bajusz, HS Seo, ...
Cancers 11 (11), 1757, 2019
52019
ProxyPhos sensors for the detection of negatively charged membranes
BI Murcar-Evans, AD Cabral, K Toutah, ED de Araujo, A Lai, ...
Analyst 142 (23), 4511-4521, 2017
52017
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia
AE Shouksmith, JM Gawel, N Nawar, D Sina, YS Raouf, S Bukhari, L He, ...
ACS Medicinal Chemistry Letters 11 (1), 56-64, 2019
42019
The system can't perform the operation now. Try again later.
Articles 1–20